Novozymes Sales and Profits Grow Strongly in 2010

Enzymes technology company Novozymes (Copenhagen) says its 2010 Ebit increased 25% to DK 2.1 billion ($382 million) on sales up 15% to DK 9.7 billion. Overall demand was high in the enzyme business, and costs were kept under control, the company says.   The outlook for 2011 is for an Ebit growth of 8-11% with a corresponding growth in sales of 7-11%. ROIC was 22.2% in 2010, compared with 20.3% in 2009, including goodwill.   “We performed very well in terms of sales, earnings, cash flow, and sustainability," says Steen Riisgaard...

This information is only available to Chemical Week subscribers.

Forgot your user ID or password?
Click here to have it sent to you.

Email Address First Name Last Name

Not an IHS Chemical Week 24/7 member yet? Here's why you should be: Searchable online archive access of the last 2 years of Chemical Week. Print or digital magazine subscription Price and market change alerts Economic data and statistics Buyers' Guides Webcasts | whitepapers